ProCE Banner Activity

Immunotherapy in Special Patient Populations and Future Directions

Slideset Download
Download this slideset from a live CCO symposium for an expert overview of data informing optimal use of immunotherapy in the treatment of special patient populations, including those with autoimmune disease, CNS metastases, or poor performance status, along with highlights of immunotherapy combination regimens under investigation.

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS, has disclosed that she has served on the advisory board for Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, NGM Pharmaceuticals, Pfizer, Roche/Genentech, and Takeda and is on the Data and Safety Monitoring Board for Daiichi Sankyo.